13/01/2021at 23:24

Novo CEO Lars Fruergaard Jørgensen hopes for Eli Lilly's future success

US firm Eli Lilly will hopefully keep up its great performance in the lucrative GLP-1 market, says Novo Nordisk CEO Lars Fruergaard Jørgensen.

Novo Nordisk CEO Lars Fruergaard Jørgensen | Photo: Stine Bidstrup/ERH

BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN

We love it the way it is right now, and for this reason, we would love it if things continued in the same way. This sentiment captures the mindset of Danish pharmaceutical firm Novo Nordisk's CEO Lars Fruergaard Jørgensen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Eli Lilly skyrockets following positive Alzheimer's data
For subscribers
Calm Novo Nordisk following Brexit: We had five years to prepare
For subscribers
Pfizer readies to compete against Ascendis and Novo Nordisk: Submits weekly growth hormone to FDA
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Per Wold-Olsen officially stepped down as GN's chair at the company's AGM | Foto: Mik Eskestad

Hearing health

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers

Regulation

CHMP recommends nine drugs in March

For subscribers

Nicolai Buhl, executive vice president for innovation at Coloplast, is busy winning a clinical contest against a catheter competitor | Foto: Mik Eskestad

Medtech

Coloplast challenges its biggest catheter competitor in clinical contest

For subscribers

Other

Top news from MedWatch this week

Pharma & biotech

Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit

For subscribers

Pharma & biotech

Novo Nordisk helps Canada resolve Ozempic issue

For subscribers

Novo Nordisk helps Canada resolve Ozempic issue

Americans were reportedly crossing the border seeking the diabetes drug with a strong weight-loss effect until barred from purchases.

For subscribers

Minister for the Interior and Health of Denmark Sophie Løhde must answer questions concerning Novo Nordisk's funding of a Danish patient group | Foto: Ida Marie Odgaard

Pharma & biotech

Danish health minister to answer questions about Novo Nordisk sponsorship of patient group

The Danish minister for health has six business days to answer questions posed by a parliamentarian.

For subscribers

Hearing health

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers